Drugs / RO7172508
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03539484 | Jul 2018 → Jul 2019 | cancer | Hoffmann-La Roche | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7172508 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03539484 ↗ |
| Route | Intravenous | “optimal schedule for intravenous (IV) and subcutaneous (SC) administrations of RO7172508” NCT03539484 ↗ |
| Route | Subcutaneous | “optimal schedule for intravenous (IV) and subcutaneous (SC) administrations of RO7172508” NCT03539484 ↗ |